Olema Pharmaceuticals (NASDAQ: OLMA) director sells 3,489 shares in Form 4

Rhea-AI Filing Summary

Olema Pharmaceuticals director Harmon Cyrus reported an open-market sale of common stock. On January 14, 2026, he sold 3,489 shares of Olema Pharmaceuticals, Inc. common stock at a weighted average price of $29.12 per share, with individual trade prices ranging from $29.00 to $29.23.

After this transaction, Cyrus beneficially owns 737,770 shares directly. He also reports 117,028 additional shares held indirectly through the Harmon Family Investors LLC, of which he is the manager.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Harmon Cyrus

(Last) (First) (Middle)

C/O OLEMA PHARMACEUTICALS, INC.

780 BRANNAN ST

(Street)

SAN FRANCISCO CA 94103

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Olema Pharmaceuticals, Inc. [ OLMA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/14/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/14/2026		S		3,489	D	$29.12(1)	737,770	D
Common Stock								117,028	I	See Footnote(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The weighted average sale price for the transaction reported was $29.12, and the range of prices were between $29.00 and $29.23. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

2. The shares are held by the Harmon Family Investors LLC, of which the Reporting Person is the manager.

	/s/ Shane Kovacs, Attorney-in-Fact	01/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Olema Pharmaceuticals (OLMA) disclose for Harmon Cyrus?

The filing reports that director Harmon Cyrus sold 3,489 shares of Olema Pharmaceuticals, Inc. common stock in an open-market transaction on January 14, 2026.

At what price did Harmon Cyrus sell Olema Pharmaceuticals (OLMA) shares?

The weighted average sale price was $29.12 per share, with individual trades executed between $29.00 and $29.23 per share.

How many Olema Pharmaceuticals shares does Harmon Cyrus own after this Form 4 transaction?

Following the reported sale, Harmon Cyrus beneficially owns 737,770 shares directly and 117,028 shares indirectly through an entity.

How are the indirect Olema Pharmaceuticals (OLMA) shares held for Harmon Cyrus?

The 117,028 indirectly held shares are owned by Harmon Family Investors LLC, an entity for which Harmon Cyrus serves as manager.

What role does Harmon Cyrus have at Olema Pharmaceuticals (OLMA)?

Harmon Cyrus is reported as a director of Olema Pharmaceuticals, Inc. on this Form 4.

Were the Olema Pharmaceuticals (OLMA) sales executed in multiple trades?

Yes. The filing states a weighted average price of $29.12 with sale prices ranging from $29.00 to $29.23, indicating multiple trade executions.